Sneha R. Sagar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Sneha R. Sagar has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Paresh K. Patel
4 shared publicationsAbha Vyas
Department of Pharmaceutical Chemistry, L.J. Institute of Pharmacy, L J University, Ahmedabad, India
1 shared publication- Aboli Girme
Pharmanza Herbal Pvt. Ltd., Anand, 388430, Gujarat, India
1 shared publication Aditi D. Kunvariya
Department of Pharmaceutical Chemistry, L.J. Institute of Pharmacy, L J University, Ahmedabad 382 210, India
1 shared publication- Akash Saggam
Ayush Center of Excellence, Center for Complementary and Integrative Health, School of Health Sciences, Savitribai Phule Pune University, Pune, 411007, India
1 shared publication Aniket Marathe
Affiliation Bioinformatics Centre, Savitribai Phule Pune University, Pune, India
1 shared publication
Latest Publications
- 7 May 2024
- Published by Springer Nature in Phytochemistry Reviews
- Vol. 24 (1) , 701-738
Phytochemistry, ethnopharmacology and novel formulations based approaches for the treatment of irritable bowel syndrome: a comprehensive review
- 7 May 2024
- Published by Springer Nature in Phytochemistry Reviews
- Vol. 24 (1) , 701-738
Phytochemistry, ethnopharmacology and novel formulations based approaches for the treatment of irritable bowel syndrome: a comprehensive review
- Open Access
- 11 June 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (6) , e0248479
Ayurveda botanicals in COVID-19 management: An in silico multi-target approach
The Coronavirus disease (COVID-19) caused by the virus SARS-CoV-2 has become a global pandemic in a very short time span. Currently, there is no specific treatment or vaccine to counter this highly contagious disease. There is an urgent need to find a specific cure for the disease and global efforts are directed at developing SARS-CoV-2 specific antivirals and immunomodulators. AyurvedicRasayanatherapy has been traditionally used in India for its immunomodulatory and adaptogenic effects, and more recently has been included as therapeutic adjuvant for several maladies. Amongst several others,Withania somnifera(Ashwagandha),Tinospora cordifolia(Guduchi) andAsparagus racemosus(Shatavari) play an important role inRasayanatherapy. The objective of this study was to explore the immunomodulatory and anti SARS-CoV2 potential of phytoconstituents from Ashwagandha, Guduchi and Shatavari using network pharmacology and docking. The plant extracts were prepared as per ayurvedic procedures and a total of 31 phytoconstituents were identified using UHPLC-PDA and mass spectrometry studies. To assess the immunomodulatory potential of these phytoconstituents anin-siliconetwork pharmacology model was constructed. The model predicts that the phytoconstituents possess the potential to modulate several targets in immune pathways potentially providing a protective role. To explore if these phytoconstituents also possess antiviral activity, docking was performed with the Spike protein, Main Protease and RNA dependent RNA polymerase of the virus. Interestingly, several phytoconstituents are predicted to possess good affinity for the three targets, suggesting their application for the termination of viral life cycle. Further, predictive tools indicate that there would not be adverse herb-drug pharmacokinetic-pharmacodynamic interactions with concomitantly administered drug therapy. We thus make a compelling case to evaluate the potential of theseRasayanabotanicals as therapeutic adjuvants in the management of COVID-19 following rigorous experimental validation.
- 11 June 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (6) , e0248479
Open AccessAyurveda botanicals in COVID-19 management: An in silico multi-target approach
The Coronavirus disease (COVID-19) caused by the virus SARS-CoV-2 has become a global pandemic in a very short time span. Currently, there is no specific treatment or vaccine to counter this highly contagious disease. There is an urgent need to find a specific cure for the disease and global efforts are directed at developing SARS-CoV-2 specific antivirals and immunomodulators. AyurvedicRasayanatherapy has been traditionally used in India for its immunomodulatory and adaptogenic effects, and more recently has been included as therapeutic adjuvant for several maladies. Amongst several others,Withania somnifera(Ashwagandha),Tinospora cordifolia(Guduchi) andAsparagus racemosus(Shatavari) play an important role inRasayanatherapy. The objective of this study was to explore the immunomodulatory and anti SARS-CoV2 potential of phytoconstituents from Ashwagandha, Guduchi and Shatavari using network pharmacology and docking. The plant extracts were prepared as per ayurvedic procedures and a total of 31 phytoconstituents were identified using UHPLC-PDA and mass spectrometry studies. To assess the immunomodulatory potential of these phytoconstituents anin-siliconetwork pharmacology model was constructed. The model predicts that the phytoconstituents possess the potential to modulate several targets in immune pathways potentially providing a protective role. To explore if these phytoconstituents also possess antiviral activity, docking was performed with the Spike protein, Main Protease and RNA dependent RNA polymerase of the virus. Interestingly, several phytoconstituents are predicted to possess good affinity for the three targets, suggesting their application for the termination of viral life cycle. Further, predictive tools indicate that there would not be adverse herb-drug pharmacokinetic-pharmacodynamic interactions with concomitantly administered drug therapy. We thus make a compelling case to evaluate the potential of theseRasayanabotanicals as therapeutic adjuvants in the management of COVID-19 following rigorous experimental validation.